Genomics

Dataset Information

0

Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin


ABSTRACT: Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear1. Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C-allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (p=6.6x10-14) greater metformin induced HbA1c reduction in 10,577 participants of European ancestry. rs8192675 is the top cis-eQTL for SLC2A2 in 1,226 human liver samples, suggesting a key role for hepatic GLUT2 in regulation of metformin action. In obese individuals C-allele homozygotes at rs8192675 had a 0.33% (3.6mmol/mol) greater absolute HbA1c reduction than T-allele homozygotes.This is about half the effect seen with the addition of a DPP-4 inhibitor, and equates to a dose difference of 550mg of metformin, suggesting rs8192675 as a potential biomarker for stratified medicine.

PROVIDER: EGAS00001001875 | EGA |

REPOSITORIES: EGA

Similar Datasets

2017-02-20 | PXD002214 | Pride
2019-07-13 | E-MTAB-7272 | biostudies-arrayexpress
2013-01-30 | E-BAIR-8 | biostudies-arrayexpress
2015-03-31 | E-GEOD-67342 | biostudies-arrayexpress
2015-03-31 | GSE67342 | GEO
2021-12-31 | GSE123677 | GEO
2023-08-10 | GSE157049 | GEO
2020-02-29 | E-MTAB-8781 | biostudies-arrayexpress
2024-07-05 | GSE238235 | GEO
2017-03-31 | MSV000080848 | MassIVE